Psychopharmacology: Declining differences in response rates with antidepressants versus placebo: A modest proposal for another contributing cause

Journal of Psychiatric Practice

Volumn 19, Issue 3, 2013, Pages 227-233

  Preskorn, Sheldon H ^a  

^a UNIVERSITY OF KANSAS SCHOOL OF MEDICINE WICHITA   (United States)

Author keywords

Antidepressants; Clinical trials; Placebo; Response rates; SNRIs; SSRIs

Indexed keywords

ANTIDEPRESSANT AGENT; CITALOPRAM; ESCITALOPRAM; FLUOXETINE; PAROXETINE; PLACEBO; SERTRALINE; VILAZODONE; SEROTONIN UPTAKE INHIBITOR;

ARTICLE; DEPRESSION; DRUG MARKETING; DRUG MECHANISM; DRUG RESPONSE; EXPERIMENTAL THERAPY; HUMAN; MAJOR DEPRESSION; PLACEBO EFFECT; PRESCRIPTION; PSYCHOLOGICAL WELL BEING; REMISSION; SEROTONIN BRAIN LEVEL; SEROTONINERGIC TRANSMISSION; TREATMENT DURATION; DEPRESSIVE DISORDER; DEPRESSIVE DISORDER, TREATMENT-RESISTANT; DRUG APPROVAL; DRUG SUBSTITUTION; DRUG UTILIZATION; FOOD AND DRUG ADMINISTRATION; PSYCHOLOGY; RANDOMIZED CONTROLLED TRIAL (TOPIC); STATISTICS AND NUMERICAL DATA; SUPPLY AND DISTRIBUTION; TREATMENT OUTCOME; UNITED STATES; PSYCHOLOGICAL ASPECT; REVIEW; STATISTICS; TREATMENT RESISTANT DEPRESSION;

ANTIDEPRESSIVE AGENTS; DEPRESSIVE DISORDER; DEPRESSIVE DISORDER, TREATMENT-RESISTANT; DRUG APPROVAL; DRUG SUBSTITUTION; DRUG UTILIZATION; HUMANS; PLACEBO EFFECT; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SEROTONIN UPTAKE INHIBITORS; TREATMENT OUTCOME; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 84885084925     PISSN: 15274160     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.pra.0000430506.37144.d1     Document Type: Article

References (24)

1. Kalia R, Mittal M, Preskorn SH. Vilazodone for major depressive disorder. Curr Psychiatry 2011;10:84-8.
2. Janicak P, Davis J, Preskorn S, et al. Principles and practice of psychopharmacotherapy, 4th edition. Baltimore, MD: Williams & Wilkins; 2006.
3. Preskorn S. What do the terms "drug-specific response/remission rate" and "placebo" really mean? J Psychiatr Pract 2011;17:420-4.
4. Preskorn SH. Understanding the basics of antidepressant pharmacology. Series of columns published in the Journal of Psychiatric Practice between 1998 and 2000 (available at www.preskorn.com/column2.html, accessed April 23, 2013).
5. Preskorn SH. CNS drug development. Part I: The early period of CNS drugs. J Psychiatr Pract 2010;16:334-9.
6. Preskorn SH. CNS drug development: Part II: Advances from the 1960s to the 1990s. J Psychiatr Pract 2010;16: 413-5.
7. Preskorn SH. CNS drug development: Part III: Future directions. J Psychiatr Pract 2011;17:49-52.
8. Preskorn SH. Outpatient management of depression, third edition. Caddo, OK: Professional Communications; 2009.
9. Harvey AT, Rudolph RL, Preskorn SH. Evidence of the dual mechanisms of action of venlafaxine. Arch Gen Psychiatry 2000;57:503-9.
10. Meyer JH, Wilson AA, Sagrati S, et al. Serotonin transporter occupancy of five selective serotonin reuptake inhibitors at different doses: An [11C]DASB positron emission tomography study. Am J Psychiatry 2004;161:826-35.
11. Preskorn SH. The use of biomarkers in psychiatric research: How serotonin transporter occupancy explains the dose-response curves of SSRIs. J Psychiatr Pract 2012;18:38-45.
12. Preskorn SH. Flat dose-response curves for efficacy: What do they mean to the clinician? J Psychiatr Pract. 2008;14: 232-6.
13. Preskorn SH. How and why study designs affect the nature and validity of study results: Appearance versus true knowledge. Part I. J Psychiatr Pract 2009;15:306-10.
14. Preskorn SH. How and why study designs affect the nature and validity of study results: Appearance versus true knowledge. Part II. J Psychiatr Pract 2009;15:402-7.
15. Warden D, Rush AJ, Trivedi MH, et al. STAR D Project results: A comprehensive review of findings. Curr Psychiatry Rep 2007;9:449-59.
16. Preskorn SH. Results of the STAR D study: Implications for clinicians and drug developers. J Psychiatr Pract 2009;15:45-9.
17. Zornberg GL. Regulatory issues. In: Kalali A, Preskorn S, Kwentus J, et al. eds. Essential CNS drug development. Cambridge, UK: Cambridge University Press; 2012:14-30.
18. Ross FJ. Statistics for the clinician: Diagnostic questionnaires. J Psychiatr Pract 2011;17:57-60.
19. Ross FJ. Hypothesis tests and p-values. J Psychiatr Pract 2011;17:288-91.
20. Kraemer HC, Morgan GA, Leech NL, et al. Measures of clinical significance J Am Acad Child Adolesc Psychiatry 2003;42:1524-9.
21. Ferguson CJ. An effect size primer: A guide for clinicians and researchers. Professional Psychology: Research and Practice 2009;40:532-8.
22. Coe R. It's the effect size, stupid: What the effect size is and why it is important. Paper presented at Annual Conference of the British Educational Research Association, University of Exeter, England, 12-14 September 2002 (available at www.leeds.ac.uk/educol/documents/00002182.htm).
23. Laupacis A, Sackett DL, Roberts RS. An assessment of clinically useful measures of the consequences of treatment. N Engl J Med 1988;318:1728-33.
24. Nuovo J, Melnikow J, Chang D. Reporting number needed to treat and absolute risk reduction in randomized controlled trials. JAMA 2002;287:2813-4.